Takeda's Hyqvia Phase 3 Trial In CIDP Patients Meets Primary Endpoint

Takeda Pharmaceutical Co. Ltd. (TAK) Thursday said its double-blind phase 3 trial of Hyqvia met the primary endpoint for the maintenance treatment of chronic inflammatory demyelinating polyradiculoneuropathy or CIDP.

The trial used 10 percent human Immune Globulin Infusion with Recombinant Human Hyaluronidase.

The results showed that Hyqvia reduced relapse of neuromuscular disability and impairment. The pharma company said analyses from ADVANCE-1 are ongoing.

The trial was in 132 adult patients CIDP autoimmune disease who had been on a stable
dosing regimen of intravenous immunoglobulin therapy for at least three
months prior to infusion.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Seffner, Florida -based Canyon Furniture Co. is recalling ladders sold with bunk bed and hutch sets citing entrapment and strangulation risks, the U.S. Consumer Product Safety Commission said. The about 2,100 units of Canyon Lake and Cottage Colors Bunk Bed and Hutch Sets were sold exclusively at Rooms To Go. Lyft announced the expansion to its partnership with Indeed in Jobs Access program. The ride-hailing company will be providing transportation access for Indeed's Ready to Work program. Indeed's Ready to Work program is a series of free virtual and in-person events for job seekers in several cities across the U.S. from September 15 to October 8, 2022. Pool and Spa drain covers imported to the United States by various companies have been recalled due to violation of the Virginia Graeme Baker Pool and Spa Safety Act, the U.S. Consumer Product Safety Commission announced. The various recalls include pool and spa drain covers manufactured in China and sold exclusively at Amazon.com for different prices ranging from $10 to $12.
Follow RTT